Paliperidone extended-release tablets: A new atypical antipsychotic

Journal of Psychosocial Nursing and Mental Health Services

Volumn 45, Issue 5, 2007, Pages 15-18

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG MONITORING; HUMAN; LONG TERM CARE; NURSE ATTITUDE; NURSING; PATIENT EDUCATION; PATIENT SELECTION; PSYCHIATRIC NURSING; REVIEW; SAFETY; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; HUMANS; ISOXAZOLES; LONG-TERM CARE; NURSE'S ROLE; PATIENT EDUCATION; PATIENT SELECTION; PSYCHIATRIC NURSING; PYRIMIDINES; SAFETY; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34250644309     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20070501-05     Document Type: Review

References (10)

1. Cleton, A., Cleton, A., Talluri, K., Leempoels, J., Thyssen, A., Janssens, L., et al. (2006). No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects [Abstract]. Clinical Pharmacology & Therapeutics, 79(2), P22.
2. Conley, R., Gupta, S.K., & Sathyan, G. (2006). Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Current Medical Research and Opinion, 22, 1879-1892.
3. Davidson, M., Emsley, R., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., et al. (2006). Efficacy, safety, and effect on functioning of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: An international 6-week placebocontrolled study [Abstract]. Schizophrenia Research, 81(Suppl. 1), 43.
4. Kane, J.M., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., & Eerdekens, M. (2005). Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: A 6-week placebo-controlled study [Abstract]. Neuropsychopharmaoology, 30(Suppl. 1), S200.
5. Karlsson, P., Dencker, E., Nyberg, S., Mannaert, E., Boom, S., Talluri, K., et al. (2006). Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies [Abstract]. Clinical Pharmacology & Therapeutics, 79(2), P74.
6. Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P., et al. (2007). Paliperidone extend-ed-release tablets for prevention of symptom recurrence in patients with schizophrenia. Journal of Clinical Psychopharmacology, 27, 6-14.
7. Marder, S.R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., & Eerdekens, M. (2005). Treatment of patients with acute schizophrenia using paliperidone extended-release tablets: A 6-week placebo-controlled study [Abstract]. Neuropsychopharmacology, 30(Suppl. 1), S191-S192.
8. Nasrallah, H.A. (2007). The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial. Journal of Clinical Psychiatry, 68(Suppl. 1), 5-11.
9. Seeman, P. (2005). An update of fast-off dopamine D2 atypical antipsychotics. American Journal of Psychiatry, 162, 1984-1985.
10. Vermeir, M., Boom, S., Naessens, 1., Talluri, K., & Eerdekens, M. (2006). Absorption, metabolism, and excretion of a single oral dose of HC-paliperidone 1 mg in five healthy male subjects [Abstract]. Clinical Pharmacology & Therapeutics, 79(2), P80.